Contrasting Emergent Biosolutions (NYSE:EBS) & Lunai Bioworks (NASDAQ:LNAI)

Lunai Bioworks (NASDAQ:LNAI) and Emergent Biosolutions (NYSE:EBS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Lunai Bioworks and Emergent Biosolutions, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1	0	0	0	1.00
Emergent Biosolutions	2	1	3	0	2.17

Emergent Biosolutions has a consensus target price of $10.00, indicating a potential upside of 65.70%. Given Emergent Biosolutions’ stronger consensus rating and higher probable upside, analysts clearly believe Emergent Biosolutions is more favorable than Lunai Bioworks.

Risk & Volatility

Lunai Bioworks has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, Emergent Biosolutions has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500.

Profitability

This table compares Lunai Bioworks and Emergent Biosolutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	N/A	-42.62%
Emergent Biosolutions	-40.16%	-0.43%	-0.15%

Valuation & Earnings

This table compares Lunai Bioworks and Emergent Biosolutions”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	$51,992.00	15.96	-$3.56 million	($0.40)	-0.41
Emergent Biosolutions	$742.90 million	0.42	$52.60 million	($5.10)	-1.18

Emergent Biosolutions has higher revenue and earnings than Lunai Bioworks. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Lunai Bioworks, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by company insiders. Comparatively, 6.0% of Emergent Biosolutions shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Emergent Biosolutions beats Lunai Bioworks on 9 of the 13 factors compared between the two stocks.

About Lunai Bioworks

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase.

About Emergent Biosolutions

Emergent BioSolutions Inc. is a life sciences company that develops, manufactures and supplies medical countermeasures for public health threats. Its portfolio has included products for protection against anthrax and smallpox, as well as treatments and emergency medicines used in overdose response and other acute-care settings. The company has also provided contract development and manufacturing services for pharmaceutical and biotechnology companies, supporting activities such as drug substance and product manufacturing, packaging and related commercialization services.